Clinical Investigation| Volume 346, ISSUE 5, P349-352, November 2013

The Role for Tunneled Indwelling Pleural Catheters in Patients With Persistent Benign Chylothorax



      Utilization of tunneled indwelling pleural catheters (TIPCs) for persistent pleural effusions is increasingly more common; however, the presence of chylothorax is generally considered a contraindication for utilization of a TIPC due to concerns regarding potential nutritional, immunologic and hemodynamic complications. Therefore, in this study, a cohort of patients with persistent benign chylothorax managed with TIPCs is described.


      A retrospective analysis of patients with persistent benign chylothorax managed with a TIPC at the study center between January 1, 2008, and March 1, 2012, was completed. Extracted data included patient characteristics, chylothorax etiologies, prior interventions, outcomes and complications.


      Eleven patients (14 hemithoraces) had persistent benign chylothorax treated with placement of a TIPC during the inclusion time frame. Etiology of the chylothorax was nontraumatic in 8 of the 11 patients, with the remaining 3 secondary to thoracic surgery. Pleurodesis was achieved in 9 of the 14 hemithoraces, with a median time to pleurodesis of 176 days. All procedures were well tolerated, and no immediate periprocedural complications were reported. One serious complication was encountered in the form of a postoperative pulmonary embolism after replacement of an occluded TIPC, resulting in the patient’s death. Two patients had transient occlusions of their TIPCs successfully treated with intracatheter thrombolytic therapy. No significant adverse nutritional, hemodynamic or immunologic outcomes were reported during follow-up for any included patient.


      Utilization of a TIPC for the management of persistent benign chylothorax should be considered early because pleurodesis may be frequently and safely achieved in this patient population.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Maldonado F.
        • Hawkins F.J.
        • Daniels C.E.
        • et al.
        Pleural fluid characteristics of chylothorax.
        Mayo Clin Proc. 2009; 84: 129-133
        • Staats B.A.
        • Ellefson R.D.
        • Budahn L.
        The lipoprotein profile of chylous and nonchylous pleural effusions.
        Mayo Clin Proc. 1980; 55: 700-704
        • Doerr C.H.
        • Allen M.S.
        • Nichols Iii F.C.
        • et al.
        Etiology of chylothorax in 203 patients.
        Mayo Clinic Proc. 2005; 80: 867-870
        • Valentine V.G.
        • Raffin T.A.
        The management of chylothorax.
        Chest. 1992; 102: 586-591
        • Machleder H.I.
        • Paulus H.
        Clinical and immunological alterations observed in patients undergoing long-term thoracic duct drainage.
        Surgery. 1978; 84: 157-165
        • Jimenez C.A.
        • Mhatre A.D.
        • Martinez C.H.
        • et al.
        Use of an indwelling pleural catheter for the management of recurrent chylothorax in patients with cancer.
        Chest. 2007; 132: 1584-1590
        • Bonner G.M.
        • Warren J.M.
        A review of the nutritional management of chyle leakage in adults.
        J Hum Nutr Diet. 1998; 11: 105-114
        • Fernández JR., Alvarez
        • Kalache K.D.
        • Graŭel E.L.
        Management of spontaneous congenital chylothorax: oral medium-chain triglycerides versus total parenteral nutrition.
        Am J Perinatol. 1999; 16: 415-420
        • Hashim S.A.
        • Roholt H.B.
        • Babayan V.K.
        • et al.
        Treatment of chyluria and chylothorax with medium-chain triglyceride.
        N Engl J Med. 1964; 270: 756-761
        • Jensen G.L.
        • Mascioli E.A.
        • Meyer L.P.
        • et al.
        Dietary modification of chyle composition in chylothorax.
        Gastroenterology. 1989; 97: 761-765
        • Deso S.
        • Ludwig B.
        • Kabutey N.K.
        • et al.
        Lymphangiography in the diagnosis and localization of various chyle leaks.
        Cardiovasc Intervent Radiol. 2012; 35: 117-126
        • Marcon F.
        • Irani K.
        • Aquino T.
        • et al.
        Percutaneous treatment of thoracic duct injuries.
        Surg Endosc. 2011; 25: 2844-2848
        • McGrath E.E.
        • Blades Z.
        • Anderson P.B.
        Chylothorax: aetiology, diagnosis and therapeutic options.
        Respir Med. 2010; 104: 1-8
        • Maldonado F.
        • Cartin-Ceba R.
        • Hawkins F.J.
        • et al.
        Medical and surgical management of chylothorax and associated outcomes.
        Am J Med Sci. 2010; 339: 314-318
        • Gupta D.
        • Ross K.
        • Piacentino Iii V.
        • et al.
        Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax.
        Ann Thorac Surg. 2004; 78: e9-e12
        • Little A.G.
        • Kadowaki M.H.
        • Ferguson M.K.
        • et al.
        Pleuro-peritoneal shunting.
        Alternative therapy for pleural effusions. Ann Surg. 1988; 208: 443-450
        • Das A.
        • Shah P.S.
        Octreotide for the treatment of chylothorax in neonates.
        Cochrane Database Syst Rev. 2010; 9: CD006388
        • Helin R.D.
        • Angeles S.T.V.
        • Bhat R.
        Octreotide therapy for chylothorax in infants and children: a brief review.
        Pediatr Crit Care Med. 2006; 7: 576-579
        • Kalomenidis I.
        Octreotide and chylothorax.
        Curr Opin Pulm Med. 2006; 12: 264-267